Autorisation d’accès précoce refusée à la spécialité QALSODY (tofersen) dans l’indication « traitement des adultes atteints de sclérose latérale amyotrophique (SLA) associée à une mutation du gène superoxyde dismutase 1 (SOD1) ».
See also
HAS opinions and decisions
22/10/2024
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
ychUZWMY8FCbCdc0
